Oliver's mTOR Atlas Evidence Platform
Reading level
Mode

Joan B. Mannick

Ran early clinical trials of low-dose mTOR inhibitors in older adults, which improved their response to flu vaccination and, in a phase 2a trial, their rate of self-reported infections; a larger phase 3 trial of RTB101 (2021) did not confirm a reduction in respiratory illness. She led this work first at Novartis and then at resTORbio

SVP & Chief Medical Officer, Altos Labs · co-founder, resTORbio · led Novartis's clinical mTOR-inhibitor aging program · MD, Harvard Medical School

Profile, Altos Labs (Redwood City, California, USA) ↗ ORCID0000-0002-9681-4126 ↗

Joan B. Mannick Portrait: Altos Labs

Joan Mannick trained in internal medicine at Harvard before moving into drug development, first at Genzyme and then, from 2010, in the New Indications Discovery Unit at Novartis. There she led the first randomized clinical trials testing whether low-dose mTOR inhibition could improve immune function in elderly volunteers, rather than just extending lifespan in animal models.

Her trials showed that low-dose mTOR inhibitors improved influenza-vaccine responses and, in a phase 2a trial, reduced the rate of self-reported infections in people over 65 (a phase 3 trial of RTB101 in 2021 did not confirm the clinical benefit) — among the first direct evidence in humans that partially inhibiting mTOR could counter an aspect of immune aging. She co-founded resTORbio, a Novartis spinout, to develop RTB101 along these lines, and has since led drug development at Life Biosciences and Tornado Therapeutics before becoming Chief Medical Officer at Altos Labs in 2025.

The timeline below follows Mannick's contributions gathered in this Atlas.

Milestones in the Atlas

A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.

YearEvidenceStudy
2014 H mTOR inhibition improves immune function in the elderly MAN2014 Reports that mTOR inhibition improves immune function in elderly volunteers, one of the first clinical demonstrations of an mTOR-targeted aging intervention in humans.
2018 H TORC1 inhibition enhances immune function and reduces infections in the elderly MAN2018 Phase 2a RCT (n=264): six weeks of low-dose BEZ235 (RTB101) plus everolimus was associated with fewer self-reported infections over the following year and a better flu-vaccine response; the later phase 3 trial of RTB101 alone did not confirm a clinical benefit (MAN2021).
2021 H Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials MAN2021 Reports phase 2b/3 randomised trial results on targeting the biology of aging with mTOR inhibitors to improve immune function in older adults.

Co-authors in the Atlas 4

People with a profile here who share at least one study with Joan B. Mannick.

ShowHide
  • David J. Glass 2 shared studies Muscle biologist and Regeneron vice president for ageing research, member of the US National Academy of Sciences, who helped discover the muscle-wasting enzymes MuRF1 and MAFbx and co-authored the first trials of low-dose mTOR inhibition in older people
  • Dean Quinn 2 shared studies Clinical trial investigator at P3 Research in Wellington, New Zealand, who was a co-author of the resTORbio trials that tested low-dose mTOR inhibitors to strengthen immunity in older adults
  • Lloyd B. Klickstein 2 shared studies A physician-scientist who led the clinical studies at Novartis showing that low-dose mTOR inhibitors can boost immune function and cut infections in older adults.
  • Sarb Shergill Senior author of the 2021 report of resTORbio's phase 2b and phase 3 trials of the mTOR inhibitor RTB101 to protect older adults from respiratory infections

Every researcher with a profile →

On the programme

Meetings in the Atlas calendar where Joan B. Mannick is listed among the speakers or organisers.

All meetings in the calendar →

← All researchers

Spotted something wrong or out of date about Joan B. Mannick?
Was this page useful?